Zimmer Biomet Holdings, Inc. (ZBH)

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Bill Nygren's Oakmark Fund recently took new positions in these undervalued stocks.

Right now is not a good time in the healthcare sector. Various companies across the space are well below highs while the broader stock market chugs along at all-time highs.

Zimmer Biomet Holdings, Inc. (ZBH) Q2 2025 Earnings Call Transcript

Zimmer Biomet Holdings, Inc. ZBH reported second-quarter adjusted earnings of $2.07 per share, up 3% year over year, beating the Street estimates of $1.99.

Zimmer Biomet gains as Q2 earnings and revenues top estimates; full-year EPS guidance raised on strong segment growth.

Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zimmer Biomet (ZBH) came out with quarterly earnings of $2.07 per share, beating the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $2.01 per share a year ago.

Zimmer Biomet Holdings raised its full-year adjusted profit forecast and beat second-quarter earnings expectations on Thursday, bolstered by accelerating demand for its hip and knee implants.

Second quarter net sales of $2.077 billion increased 7.0% on a reported basis, 5.4% on a constant currency1 basis and 2.8% on an organic constant currency1 basis Second quarter diluted earnings per share were $0.77; adjusted1 diluted earnings per share were $2.07, an increase of 3.0% Company tightens full-year 2025 reported, constant currency1 and organic constant currency1 revenue growth guidance to 6.7% - 7.7%, 6.2% - 7.2% and 3.5% - 4.5%, respectively, and increases adjusted1 earnings per share financial guidance to $8.10 - $8.30 WARSAW, Ind. , Aug. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2025.

Get a deeper insight into the potential performance of Zimmer (ZBH) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

ZBH's Q2 results may show strength in Hips, Knees, and S.E.T. despite a projected year-over-year earnings dip.

Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

I reiterate my Buy rating on Zimmer Biomet Holdings, Inc., setting a fair value of $133 per ZBH share due to strong business acceleration opportunities. The Monogram Technologies acquisition could significantly enhance Zimmer's knee robotics, positioning it to better compete with Stryker through advanced autonomous technology. Paragon 28's integration is on track and expected to boost Zimmer's foot and ankle portfolio, contributing to topline growth in a fast-expanding market.

Zimmer Biomet eyes long-term gains with the $177M Monogram buyout, aiming to expand its robotic knee surgery offerings by 2027.